Current systemic therapies for metastatic renal cell carcinoma in older adults: A comprehensive review
| Autor: | Manuel Caitano Maia, Paulo Gustavo Bergerot, Sumanta K. Pal, Simone Fernandes dos Santos, Lorena Almeida, Jacob J. Adashek |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
Vascular Endothelial Growth Factor A Drug medicine.medical_specialty media_common.quotation_subject Population Disease 03 medical and health sciences Social support Antineoplastic Agents Immunological 0302 clinical medicine Renal cell carcinoma Humans Medicine Molecular Targeted Therapy 030212 general & internal medicine education Intensive care medicine Carcinoma Renal Cell Geriatric Assessment Protein Kinase Inhibitors Aged Randomized Controlled Trials as Topic media_common Aged 80 and over Polypharmacy education.field_of_study business.industry Age Factors Interferon-alpha medicine.disease Kidney Neoplasms Treatment efficacy Oncology Tolerability 030220 oncology & carcinogenesis Interleukin-2 Female Geriatrics and Gerontology business |
| Zdroj: | Journal of Geriatric Oncology. 9:265-274 |
| ISSN: | 1879-4068 |
| Popis: | Physiological changes that occur during the aging process may impact drug metabolism and availability, consequently affecting treatment efficacy and tolerability. Despite being a disease of older adults, there is little data to guide treatment decisions for older patients with metastatic renal cell carcinoma (mRCC). The recent approval of many new agents for this disease poses a clinical challenge: how to best utilize these drugs in a population (older adults) who has been generally under-represented in clinical studies. Additionally, the presence of comorbid conditions, polypharmacy, frailty, and lack of social support place this group of patients in a very unique situation. In order to avoid under-treatment, international societies' guidelines recommend routine use of geriatric tools to assess patients' suitability for systemic treatments. Here we provide a thorough review of age-related metabolic differences, safety and efficacy data for each drug approved for mRCC, and cover specific considerations for the management of older adults with this disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect